GSK’s mo-rez posts durable activity in platinum-resistant ovarian cancer as phase 3 program expands
GSK’s mocertatug rezetecan, or mo-rez, is moving from early signal to late-stage strategy with unusual speed. Fresh data from the ongoing Behold-1 study, presented at ESMO 2026, add duration and disease-control detail to an already familiar response rate in platinum-resistant ovarian cancer, the setting where therapeutic options are often short-lived and remissions are measured in months rather than seasons.
Among 45 patients with platinum-resistant ovarian cancer treated at the selected phase 3 dose of 5.8 mg/kg, the confirmed objective response rate reached 62%. Median duration of response was 12.2 months, and median progression-free survival reached 11.1 months at about 13 months of follow-up. The ORR matched the earlier April readout, but the later data sharpen the clinical picture: responses were not only frequent, they endured long enough to matter in a disease known for rapid relapse after treatment.
That durability is the central story.
In platinum-resistant disease, a median PFS of 11.1 months stands well beyond the six- to eight-month range typically expected for this patient population, a point GSK’s global head of oncology R&D, Hesham Abdullah, emphasized during a media call. The biology of the target helps explain why the result drew attention. B7-H4 is widely expressed in gynecologic cancers and relatively low in normal tissues, making it an appealing antibody-drug conjugate target for a malignancy that often evades standard chemotherapy through resistance pathways and heterogeneous tumor signaling.
Why the response profile matters in a hard-to-treat gynecologic setting
The clinical appeal of an ADC in platinum-resistant ovarian cancer rests on more than cytotoxic potency. By linking a tumor-targeting antibody to a payload, the drug concentrates damage where malignant cells express the relevant antigen, ideally preserving enough normal tissue to keep treatment on course. In practice, the margin between efficacy and hematologic toxicity is often narrow, especially with topoisomerase I inhibitor payloads, which tend to produce myelosuppression and other blood-related adverse effects.
Mo-rez appears to be operating in that familiar ADC tension. In the 45 patients receiving the phase 3 dose, 71% experienced a treatment-related adverse event of grade 3 or higher, and most of these events were hematologic. One patient discontinued treatment because of a treatment-related adverse event, and one case of interstitial lung disease occurred. Those are not trivial safety findings, and they will sit under a brighter spotlight as the program enters confirmatory trials.
Still, the duration data lend support to the current development strategy. A median duration of response of 12.2 months suggests that, when the drug works, it can hold disease control for a meaningful stretch. In a setting where many patients cycle through successive lines of therapy with diminishing returns, that kind of persistence is often what separates a transient signal from a plausible registrational path.
Toxicity management will shape how the phase 3 readouts are interpreted
Abdullah pointed to the topoisomerase I inhibitor payload as the main driver of the toxicity profile, and that explanation fits the adverse-event pattern reported so far. Hematologic toxicity is expected with this class, and it becomes especially important when the program moves from flexible early-stage management into a more standardized phase 3 framework. During earlier studies, investigators could decide whether to use growth factors or other prophylactic medications to limit side effects. In the phase 3 program, GSK has moved to a more prescriptive approach.
The change matters because supportive care can reshape tolerability, dose continuity, and ultimately the efficacy story. If prophylactic growth factor use reduces neutropenia-related interruptions, later trials may show a cleaner safety profile and a more reliable exposure-response relationship. If toxicity remains high despite tighter management, the program will need to show that the antitumor effect is strong enough to justify the tradeoff.
This is where late-stage development becomes more than a larger version of phase 1. The same response rate can look very different once treatment rules are standardized, follow-up is longer, and investigators are no longer optimizing supportive care case by case. A 71% grade 3 or higher TRAE rate in an early cohort does not automatically predict the final phase 3 experience, but it does set expectations for what will need to be controlled.
Five phase 3 trials, one fast-moving ADC strategy
GSK is already running five phase 3 studies of mo-rez: three in ovarian cancer across different resistance settings and two in endometrial cancer. The breadth of that program suggests the company views B7-H4 as more than a single-disease bet. It is attempting to establish the target across gynecologic malignancies where expression is biologically plausible and unmet need remains high.
The pace of development has also been a point of emphasis. Abdullah described the move from phase 1b to phase 3 in roughly 18 months, a compressed timeline that reflects both confidence in the asset and the pressure to secure an edge in a crowded ADC field. For GSK, mo-rez sits alongside another Hansoh-licensed ADC, ris-rez, creating a broader oncology portfolio strategy centered on antibody-drug conjugates rather than a single program.
The company’s interest in ADCs is not happening in isolation. Big Pharma has been leaning heavily into this class, and the competitive tempo is rising. Yet mo-rez’s data remain most relevant in the clinic, where the question is whether a B7-H4-directed ADC can hold up across randomized studies in tumors that have already exhausted standard platinum options.
What the current data can and cannot answer
The available dataset supports development, but it does not settle the case. The cohort is small, the follow-up is still limited, and the reported outcomes come from selected patients treated at the dose now being advanced into phase 3. Efficacy and toxicity in a broader randomized population could differ, especially once supportive care is standardized and comparison arms are introduced.
Interstitial lung disease, although limited to one case here, will also remain under scrutiny. ADC programs with topoisomerase I inhibitor payloads have taught the field to watch carefully for pulmonary toxicity, particularly when treatment duration extends and cumulative exposure rises. The balance between sustained response and chronic toxicity will determine whether mo-rez can translate this early signal into a durable phase 3 success.
For now, the data do something GSK clearly needed: they extend the response story beyond a headline ORR and show that disease control can persist in a population where control is usually fragile. The next readouts will need to show whether that pattern survives larger numbers, longer follow-up, and the discipline of late-stage trial design.